Xeris Pharmaceuticals | XERS - Net Income



Xeris Pharmaceuticals reported $-1930000 in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Adcock Ingram Holdings ZAR 389.71M 19.87M Dec/2024
Celltrion KRW 108.67B 127.98B Mar/2025
Cspc Pharmaceutical CNY 1.48B 927.97M Mar/2025
Dianthus Therapeutics USD -31629000 3.19M Jun/2025
Divis Laboratories Ltd 5.45B 1.17B Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Kangmei Pharma CNY 8.4M 110.17K Jun/2025
Knight Therapeutics CAD 85K 2.03M Sep/2024
Laboratorios Farma EUR 21.64M 70.9M Jun/2025
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 304K 15.32M Dec/2024
Neuren Pharmaceuticals AUD 134.03M 126.01M Dec/2024
Organigram Holdings CAD -6290000 16.67M Jun/2025
Pacira USD -4847000 9.66M Jun/2025
Perrigo USD -8400000 2M Jun/2025
Pharma Mar EUR 23.37M 27.32M Jun/2025
Qiagen NV USD 96.25M 5.49M Jun/2025
Sartorius EUR 32.5M 15.9M Jun/2025
Sino Biopharmaceutical CNY 482.67M 2.53B Dec/2024
Supernus Pharmaceuticals USD 22.5M 34.33M Jun/2025
Tilray USD -85342000 46.18M Nov/2024
Zz Pientze Pharmaceu 442.53M 557.25M Jun/2025